Consumer Research2020-11-05T23:41:25-08:00

Consumer Research

Cannabis in Psychedelic Therapy: Potential and Precautions

LOS ANGELES- The integration of cannabis into psychedelic-assisted psychotherapy is gaining attention as a potential treatment for various mental health conditions, including post-traumatic stress disorder (PTSD), depression, and anxiety. This approach involves administering cannabis in ...

Cybin Partners with Thermo Fisher for U.S. Manufacturing

LOS ANGELES- Cybin Inc. a neuropsychiatry company, has announced a collaboration with Thermo Fisher Scientific to support the Phase 3 clinical supply and potential commercial manufacturing of CYB003, its proprietary deuterated psilocin analog, for the ...

Rubicon Organics Appoints Glen Ibbott as Interim CFO

LOS ANGELES- Rubicon Organics Inc.  a Canadian producer of certified organic cannabis products, has appointed Glen Ibbott as Interim Chief Financial Officer, effective May 15, 2025. This leadership change follows the departure of Janis Risbin ...

TILT Holdings Reports First Quarter 2025 Financial Results

LOS ANGELES- TILT Holdings Inc. announced its financial results for the first quarter ended March 31, 2025, reflecting a year-over-year revenue decline and continued strategic realignment towards its Jupiter inhalation technology business. Financial Performance The ...

High-Paying Roles in the Cannabis Industry

LOS ANGELES- As the cannabis industry continues its expansion across the United States, it presents a variety of high-paying career opportunities. Positions such as cultivation directors, compliance officers, and extraction technicians are in demand, offering ...

  • Fast Buds - German cannabis legalisation

German Medical Cannabis Market Sees Significant Growth

LOS ANGELES- Germany's medical cannabis industry is experiencing substantial growth, driven by recent regulatory reforms and increasing patient demand. Companies such as Cantourage are at the forefront of this expansion, capitalizing on the evolving legal ...

Silo Pharma Initiates Safety Study for PTSD Drug SPC-15

LOS ANGELES- Silo Pharma Inc. a developmental-stage biopharmaceutical company, has commenced a 7-day safety and toxicology study for its lead candidate, SPC-15, an intranasal treatment targeting post-traumatic stress disorder (PTSD). The study is being conducted ...

  • Village Farms International

Village Farms International Reports Q1 2025

LOS ANGELES- Village Farms International Inc. has announced its financial results for the first quarter of 2025, highlighting a strategic pivot towards its cannabis operations and the privatization of certain fresh produce assets. For the ...

Cybin Secures Additional U.S. Patent for CYB003

LOS ANGELES- Cybin Inc. a biopharmaceutical company, announced the granting of U.S. patent 12,291,499 by the United States Patent and Trademark Office. This patent pertains to pharmaceutical compositions and oral dosage forms within the company's ...

Cronos Group Reports First Quarter 2025

LOS ANGELES- Cronos Group Inc. reported its financial results for the first quarter ended March 31, 2025, indicating a net revenue of $32.3 million, a 28% increase compared to the same period in 2024. The ...

THC Design Repositions for National Expansion

LOS ANGELES- THC Design, a California-based cannabis company, has undertaken a comprehensive rebranding initiative in collaboration with New York creative studio Super Okay. The effort aims to transition the company from a regional entity to ...

Maine Considers Stricter Medical Cannabis Regulations

LOS ANGELES- Maine lawmakers are evaluating two legislative proposals aimed at enhancing safety standards within the state's medical cannabis program. The bills, LD 104 and LD 1847, seek to introduce mandatory testing for contaminants and ...

Organigram to Announce Q2 Fiscal 2025 Results

LOS ANGELES- Organigram Global Inc. is scheduled to release its financial results for the second quarter of fiscal 2025, ending March 31, on Monday, May 12, 2025, before market open. The company will host a ...

Subscribe To Our Newsletter

Go to Top